Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411657 | 0.74 | CYP1A2 (0.45) | NUDT1ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL5656584 | 0.73 | ALDH1A1 (0.34) | ALDH1A1POLBGAASMN1; SMN2HTT | |
| SCHEMBL5751117 | 0.71 | TNKS2 (0.40) | ALDH1A1KDM4EGAASMN1; SMN2HPGD | |
| SCHEMBL442600 | 0.69 | IDO1 (0.39) | EP300KAT2BKAT8ALDH1A1KDM4E | |
| SCHEMBL6179959 | 0.69 | GPR3 (0.37) | ALDH1A1KDM4EPOLBGAASMN1; SMN2 | |
| SCHEMBL4461176 | 0.69 | GPR3 (0.37) | ALDH1A1KDM4EPOLBGAASMN1; SMN2 | |
| SCHEMBL1146962 | 0.69 | NCF1 (0.47) | KDM1ANUDT1ALDH1A1KDM4EPOLB | |
| SCHEMBL9479290 | 0.69 | CYP1A2 (0.38) | ALDH1A1KDM4EPOLBGAASMN1; SMN2 | |
| SCHEMBL1826639 | 0.69 | MAOA (0.41) | ALDH1A1KDM4EGAASMN1; SMN2TSHR | |
| SCHEMBL2300258 | 0.69 | BACE1 (0.36) | NUDT1ALDH1A1KDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | claimed |
| US-6858608-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMS S.A. | 2004-03-18 | — | — | US | claimed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | claimed |
| US-6645964-B1 | 1,3,5-Triazine compounds substituted with aromatic N-heterocycle; anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2003-11-11 | — | — | US | claimed |
| EP-1351957-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2003-10-15 | — | — | EP | claimed |
| EP-1244650-B1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA SA (FR) | 2003-06-25 | — | — | EP | claimed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | claimed |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA SA (FR) | 2003-04-24 | — | — | US | claimed |
| US-20030013711-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2003-01-16 | — | — | US | claimed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | claimed |
| EP-1244650-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2002-10-02 | — | — | EP | claimed |
| WO-2002068408-A1 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-ELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-09-06 | — | — | WO | claimed |
| WO-2002055515-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-07-18 | — | — | WO | claimed |
| WO-2001040218-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2001-06-07 | — | — | WO | claimed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| WO-2002068408-A1 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-ELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002055515-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001040218-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | KDM1A 1893/4885ACP1 1314/4885CLK4 4623/4885 |
| US-20030013711-A1 | Chemical derivatives and their application as antitelomerase agents | NTPCR, DPYD, NME1 | KDM1A 2848/4885ACP1 1989/4885CLK4 3467/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | KDM1A 2903/4885ACP1 1582/4885CLK4 3526/4885 |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | KDM1A 2949/4885ACP1 1767/4885CLK4 3502/4885 |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | KDM1A 1802/4885ACP1 1457/4885CLK4 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.